SU6 Stock Overview Provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Surmodics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Surmodics Historical stock prices Current Share Price US$33.60 52 Week High US$38.80 52 Week Low US$23.60 Beta 1.21 1 Month Change -9.68% 3 Month Change -1.75% 1 Year Change 14.29% 3 Year Change -5.62% 5 Year Change -12.09% Change since IPO 71.74%
Recent News & Updates
Surmodics, Inc., Annual General Meeting, Feb 06, 2025 Dec 20
Full year 2024 earnings released: US$0.82 loss per share (vs US$0.11 loss in FY 2023) Nov 07
Insufficient new directors Nov 01
Surmodics Announces Early Results from PROWL Registry Study of Real-World Limb Ischemia Patients Treated with Pounce Thrombectomy System Oct 31
Surmodics Receives FDA 510(k) Clearance for Pounce XL Thrombectomy System, Expanding the Pounce Thrombectomy Platform to Larger Peripheral Arteries up to 10 mm in Diameter Oct 02
Surmodics, Inc. Suspends Earnings Guidance for the Fiscal 2024 Jul 31 See more updates
Surmodics, Inc., Annual General Meeting, Feb 06, 2025 Dec 20
Full year 2024 earnings released: US$0.82 loss per share (vs US$0.11 loss in FY 2023) Nov 07
Insufficient new directors Nov 01
Surmodics Announces Early Results from PROWL Registry Study of Real-World Limb Ischemia Patients Treated with Pounce Thrombectomy System Oct 31
Surmodics Receives FDA 510(k) Clearance for Pounce XL Thrombectomy System, Expanding the Pounce Thrombectomy Platform to Larger Peripheral Arteries up to 10 mm in Diameter Oct 02
Surmodics, Inc. Suspends Earnings Guidance for the Fiscal 2024 Jul 31
Investor sentiment improves as stock rises 21% May 31 GTCR LLC entered into a definitive agreement to acquire Surmodics, Inc. (NasdaqGS:SRDX) for approximately $620 million. May 30
Investor sentiment improves as stock rises 25% May 08
Surmodics, Inc. Revises Earnings Guidance for the Fiscal Year 2024 May 03
Second quarter 2024 earnings released: EPS: US$0.017 (vs US$0.55 loss in 2Q 2023) May 02
Surmodics, Inc. to Report Q2, 2024 Results on May 01, 2024 Apr 21
Surmodics, Inc. Provides Earnings Guidance for the Fiscal Year 2024 Feb 02
First quarter 2024 earnings released: US$0.056 loss per share (vs US$0.56 loss in 1Q 2023) Feb 02
Surmodics, Inc. Announces Successful Early Clinical Use of its Pounce LP Thrombectomy System Jan 22
Surmodics, Inc. to Report Q1, 2024 Results on Feb 01, 2024 Jan 17
Surmodics, Inc., Annual General Meeting, Feb 08, 2024 Dec 19 Surmodics, Inc. Announces 24-Month Data from the Swing Trial Presented At VEITHsymposium
Full year 2023 earnings released: US$0.11 loss per share (vs US$1.96 loss in FY 2022) Nov 09
Surmodics, Inc. Provides Earnings Guidance for the Fiscal Year 2024 Nov 09
Surmodics, Inc. Announces Swing Trial 24-Month Data to Be Presented At Veith Symposium on November 15 Nov 08
Surmodics, Inc. Announces Launch of Preside Medical Device Coating Technology, Providing Lubricity and Durability to a Broader Range of Complex Device Applications Nov 01
Surmodics, Inc. to Report Q4, 2023 Results on Nov 08, 2023 Oct 11
Third quarter 2023 earnings released: EPS: US$0.52 (vs US$0.41 loss in 3Q 2022) Aug 03
Surmodics, Inc. Revises Earnings Guidance for the Fiscal Year Ending September 30, 2023 Aug 03
Surmodics, Inc. to Report Q3, 2023 Results on Aug 02, 2023 Jul 13 Surmodics, Inc.(NasdaqGS:SRDX) dropped from Russell 2000 Growth-Defensive Index
Surmodics, Inc. Receives FDA Approval for the SurVeil Drug-Coated Balloon Jun 21
Surmodics Receives FDA 510(k) Clearance for Pounce LP Thrombectomy System Jun 15
Second quarter 2023 earnings released: US$0.55 loss per share (vs US$0.29 loss in 2Q 2022) Apr 27
First quarter 2023 earnings released: US$0.56 loss per share (vs US$0.20 loss in 1Q 2022) Feb 08
Surmodics, Inc. Revises Earnings Guidance for the Fiscal Year 2023 Feb 07
Surmodics, Inc. to Report Q1, 2023 Results on Feb 06, 2023 Jan 27
Surmodics Provides Regulatory Update Related to its FDA Premarket Approval Application for the SurVeil Drug-Coated Balloon Jan 20
Full year 2022 earnings released: US$1.96 loss per share (vs US$0.31 profit in FY 2021) Nov 24
Insufficient new directors Nov 16
Full year 2022 earnings released: US$1.96 loss per share (vs US$0.31 profit in FY 2021) Nov 10
Surmodics, Inc. Provides Earnings Guidance for the Fiscal Year 2023 Nov 10
Surmodics, Inc. Announces 24-Month Data from Its Transcend Clinical Trial At the Vascular InterVentional Advances Nov 03
Surmodics, Inc. to Report Q4, 2022 Results on Nov 09, 2022 Oct 29
Surmodics, Inc. Announces TRANSCEND Trial 24-Month Data to be Presented at VIVA 2022 Oct 27
Surmodics, Inc. Announces 6-Month Data from the Surmodics SWING BTK First-in-Human Trial Presented at AMP Europe Oct 12
Third quarter 2022 earnings released: US$0.41 loss per share (vs US$0.24 loss in 3Q 2021) Jul 28
Surmodics, Inc. Updates Earnings Guidance for the Fiscal Year 2022 Jul 28
Surmodics, Inc. to Report Q3, 2022 Results on Jul 27, 2022 Jul 20
Second quarter 2022 earnings released: US$0.29 loss per share (vs US$0.59 profit in 2Q 2021) Apr 28 Surmodics, Inc. Revises Earnings Guidance for the Full Year Ended September 30, 2022
Insufficient new directors Apr 27
Surmodics, Inc. to Report Q2, 2022 Results on Apr 27, 2022 Apr 20
First quarter 2022 earnings: EPS in line with expectations, revenues disappoint Feb 04
Surmodics, Inc. Reiterates Earnings Guidance for the Year 2022 Feb 04
Independent Director recently sold €146k worth of stock Dec 01
Full year 2021 earnings released: EPS US$0.31 (vs US$0.083 in FY 2020) Nov 11
Third quarter 2021 earnings released: US$0.24 loss per share (vs US$0.18 profit in 3Q 2020) Aug 05
Insider recently sold €110k worth of stock May 26
Surmodics, Inc. Provides Earnings Guidance for the Fiscal Year 2021 Apr 29
Surmodics, Inc. Provides No Earnings Guidance for 2021 Feb 10
Surmodics, Inc. to Report Q1, 2021 Results on Feb 09, 2021 Feb 02
Surmodics, Inc. Announces 12-Month Data from its TRANSCEND Clinical Trial Has Been Presented at the Leipzig Interventional Course (LINC) 2021 Virtual Event Jan 26
Surmodics, Inc., Annual General Meeting, Feb 11, 2021 Dec 23
Surmodics, Inc. Announces Shawn T McCormick to Resign as Member of the Board of Directors, Effective December 15, 2020 Nov 19
Surmodics, Inc. Announces 6-Month Data from the Avess™ AV Fistula DCB First-In-Human Study Presented At Viva 2020 Nov 10
Surmodics, Inc. Not to Provide Earnings Guidance for the Fiscal Year 2021 Nov 06
Full year 2020 earnings released: EPS US$0.083 Nov 05
Revenue beats expectations Nov 05
Surmodics, Inc. to Report Q4, 2020 Results on Nov 04, 2020 Oct 28 Thomas A. Greaney Intends to Resign as Chief Operating Officer of Surmodics, Inc
Surmodics, Inc. Announces Not to Provide Financial Guidance Aug 07 Shareholder Returns SU6 DE Medical Equipment DE Market 7D -4.5% 2.9% 1.9% 1Y 14.3% -1.0% 15.1%
See full shareholder returns
Return vs Market: SU6 matched the German Market which returned 15.2% over the past year.
Price Volatility Is SU6's price volatile compared to industry and market? SU6 volatility SU6 Average Weekly Movement 3.6% Medical Equipment Industry Average Movement 6.2% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.2% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: SU6 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: SU6's weekly volatility (4%) has been stable over the past year.
About the Company Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for neurovascular, peripheral, coronary, and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths.
Show more Surmodics, Inc. Fundamentals Summary How do Surmodics's earnings and revenue compare to its market cap? SU6 fundamental statistics Market cap €489.32m Earnings (TTM ) -€13.90m Revenue (TTM ) €121.02m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) SU6 income statement (TTM ) Revenue US$125.45m Cost of Revenue US$31.93m Gross Profit US$93.52m Other Expenses US$107.93m Earnings -US$14.41m
Last Reported Earnings
Dec 31, 2024
Earnings per share (EPS) -1.01 Gross Margin 74.55% Net Profit Margin -11.48% Debt/Equity Ratio 26.5%
How did SU6 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/31 03:55 End of Day Share Price 2025/01/31 00:00 Earnings 2024/12/31 Annual Earnings 2024/09/30
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Surmodics, Inc. is covered by 12 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution null null Argus Research Company Daniel Owczarski Avondale Partners Michael Petusky Barrington Research Associates, Inc.
Show 9 more analysts 
